These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 26689922)
1. Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target? St-Amour I; Cicchetti F; Calon F Acta Neuropathol; 2016 Apr; 131(4):481-504. PubMed ID: 26689922 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle? Sarazin M; Dorothée G; de Souza LC; Aucouturier P Biol Psychiatry; 2013 Sep; 74(5):329-32. PubMed ID: 23683656 [TBL] [Abstract][Full Text] [Related]
7. The role of the immune system in Alzheimer disease: Etiology and treatment. Jevtic S; Sengar AS; Salter MW; McLaurin J Ageing Res Rev; 2017 Nov; 40():84-94. PubMed ID: 28941639 [TBL] [Abstract][Full Text] [Related]
8. Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies. Liu YH; Zeng F; Wang YR; Zhou HD; Giunta B; Tan J; Wang YJ Drug Discov Today; 2013 Dec; 18(23-24):1212-20. PubMed ID: 23954180 [TBL] [Abstract][Full Text] [Related]
9. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Li Y; Liu Y; Wang Z; Jiang Y Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611 [TBL] [Abstract][Full Text] [Related]
10. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Alzheimer's disease. Gelinas DS; DaSilva K; Fenili D; St George-Hyslop P; McLaurin J Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14657-62. PubMed ID: 15297619 [TBL] [Abstract][Full Text] [Related]
12. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Gong B; Pan Y; Zhao W; Knable L; Vempati P; Begum S; Ho L; Wang J; Yemul S; Barnum S; Bilski A; Gong BY; Pasinetti GM Mol Immunol; 2013 Dec; 56(4):619-29. PubMed ID: 23911420 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Alzheimer's disease: where do we stand? Where should we go? von Bernhardi R J Alzheimers Dis; 2010; 19(2):405-21. PubMed ID: 20110590 [TBL] [Abstract][Full Text] [Related]
14. Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target? Shi M; Chu F; Tian X; Aerqin Q; Zhu F; Zhu J Neuroscientist; 2022 Jun; 28(3):254-270. PubMed ID: 33530843 [TBL] [Abstract][Full Text] [Related]
15. Improved cognitive and memory abilities in a patient with Alzheimer's disease treated with activated immune cells: Immune cell therapy may benefit more AD patients. Laumbacher B; Fellerhoff-Loesch B; Wank R Med Hypotheses; 2017 Feb; 99():19-22. PubMed ID: 28110690 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
18. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice. Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784 [TBL] [Abstract][Full Text] [Related]